Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year

Table 2 Baseline characteristics of biologic-naïve patients by APR levels

	Neither APR elevated	APR levels discordant	Both APR elevated	P value
	n = 1,012	n = 487	n = 324
Age (years)	60.92 ± 13.49	63.24 ± 13.51	64.26 ± 12.79	<0.0001
Duration of RA (years)	8.62 ± 9.37	9.55 ± 10.46	7.47 ± 8.38	0.0074
One-year follow-up duration (days)	363.43 ± 29.79	364.78 ± 31.48	365.43 ± 31.72	0.5196
mHAQ	0.29 ± 0.38	0.38 ± 0.43	0.48 ± 0.53	<0.0001
CDAI	12.54 ± 10.18	14.61 ± 11.21	19.04 ± 14.91	<0.0001
Tender joints	3.53 ± 5.14	4.10 ± 5.46	5.68 ± 6.92	<0.0001*
Swollen joints	4.19 ± 5.41	4.76 ± 5.53	6.92 ± 6.73	<0.0001*
Patient global assessment	28.47 ± 23.70	34.31 ± 25.08	39.04 ± 27.26	<0.0001
MD global assessment	19.73 ± 15.59	23.22 ± 18.46	31.20 ± 23.03	<0.0001
Prednisone use	247 (24.41%)	138 (28.34%)	124 (38.27%)	<0.0001
Methotrexate use	696 (68.77%)	322 (66.12%)	191 (58.95%)	0.0050

^*Log-linear model (Poisson) - χ² test. APR, acute phase reactant; RA, rheumatoid arthritis; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.

ISSN: 1478-6362